title: Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.
authors.forename: C
authors.initials: C
authors.lastname: Schulz-Du Bois
authors.forename: A C
authors.initials: AC
authors.lastname: Schulz-Du Bois
authors.forename: B
authors.initials: B
authors.lastname: Bewig
authors.forename: I
authors.initials: I
authors.lastname: Gerstner
authors.forename: J B
authors.initials: JB
authors.lastname: Aldenhoff
authors.forename: I
authors.initials: I
authors.lastname: Cascorbi
authors.forename: M
authors.initials: M
authors.lastname: Ufer
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000506:poisoning; D017291:Clarithromycin / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000097:blood* / Q000493:pharmacokinetics / Q000506:poisoning; D004347:Drug Interactions; D062787:Drug Overdose; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D000069348:Quetiapine Fumarate
chemical_list: D000900:Anti-Bacterial Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017291:Clarithromycin